(Q34038801)

30 July 2017

1 reference

title

Development of dendritic-cell based prostate cancer vaccine (English)

1 reference

30 July 2017

1 reference

1 reference

Tjoa BA

1

1 reference

30 July 2017

Murphy GP

series ordinal

2

1 reference

30 July 2017

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

74

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

87-93

1 reference

Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Brachytherapy (seed implantation) for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Patterns of care for invasive cervical cancer. Results of a national survey of 1984 and 1990

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Orchidectomy and oestrogen therapy revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Targeted toxins as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

1 reference

7 January 2021

T cell tolerance by clonal elimination in the thymus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

1 reference

7 January 2021

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Structure of peptides associated with class I and class II MHC molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Antigen-presenting cell types

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Antigen processing for amateurs and professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

New insights into the mobilization and phagocytic activity of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Dendritic cells: migratory cells that are attractive

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Influence of dendritic cells on tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

Follow-up evaluation of a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900254-6

7 January 2021

10.1016/S0165-2478(00)00254-6

Identifiers

DOI

1 reference

30 July 2017

1 reference